Product
Tirzepatide
Aliases
LY3298176, Mounjaro, Zepbound
Name
MOUNJARO
INN Name
tirzepatide
FDA Approved
Yes
59 clinical trials
1 organization
27 indications
2 documents
Indication
ObesityIndication
Diabetes MellitusIndication
Type 2Indication
Type 2 DiabetesIndication
HealthyIndication
Metabolism and Nutrition DisordersIndication
Type 2 Diabetes MellitusIndication
Sleep ApneaIndication
Glucose Metabolism DisordersIndication
Endocrine System DiseasesIndication
Metabolic disorderIndication
chronic kidney diseaseIndication
Non-alcoholic SteatohepatitisIndication
Chronic Kidney DiseaseIndication
End-Stage Renal DiseaseIndication
Liver InsufficiencyIndication
Osteoarthritis, KneeIndication
OsteoarthritisIndication
KneeIndication
AtherosclerosisIndication
Wolfram SyndromeIndication
Metabolic HealthIndication
Unintentional Weight LossIndication
Weight GainIndication
Type 1 Diabetes MellitusIndication
Severe ObesityClinical trial
The Impact of Tirzepatide on Gastric Emptying (GE) in Overweight/Obese Non-diabetic Subjects and in Overweight/Obese Subjects With Type 2 Diabetes MellitusStatus: Completed, Estimated PCD: 2021-01-07
Clinical trial
Pharmacokinetics, Safety, and Tolerability of a Solution Formulation of LY3298176 in Healthy SubjectsStatus: Completed, Estimated PCD: 2018-12-27
Clinical trial
Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)Status: Completed, Estimated PCD: 2022-12-27
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Tirzepatide Monotherapy Compared With Placebo in Chinese Participants With Type 2 DiabetesStatus: Active (not recruiting), Estimated PCD: 2024-09-24
Clinical trial
A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide in Adults Who Have Obesity or Overweight With Weight Related ComorbiditiesStatus: Active (not recruiting), Estimated PCD: 2024-11-06
Clinical trial
A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes MellitusStatus: Completed, Estimated PCD: 2017-06-26
Clinical trial
Efficacy and Safety of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly Compared to Tirzepatide 15 mg s.c. Once-weekly in Participants With ObesityStatus: Recruiting, Estimated PCD: 2025-08-27
Clinical trial
A Multiple Dose Combination Study to Evaluate the Safety and Tolerability of Tirzepatide and LY3841136 in Overweight and Obese ParticipantsStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
Efficacy and Safety of Tirzepatide Once Weekly in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-2)Status: Completed, Estimated PCD: 2023-03-16
Clinical trial
An Open-Label, Single-Arm, Phase 4 Study to Assess Glycemic Control When Adults With Type 2 Diabetes Switch From a GLP-1 RA to Tirzepatide (SURPASS-SWITCH-2)Status: Completed, Estimated PCD: 2023-10-31
Clinical trial
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)Status: Active (not recruiting), Estimated PCD: 2022-04-01
Clinical trial
A Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 DiabetesStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Study to Evaluate Tirzepatide Concentrations in Breastmilk Following Administration of Single Dose of Tirzepatide by Subcutaneous Injection in Healthy Lactating FemalesStatus: Completed, Estimated PCD: 2024-03-12
Clinical trial
Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (SURMOUNT-ADOLESCENTS)Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With ObesityStatus: Active (not recruiting), Estimated PCD: 2027-10-07
Clinical trial
A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Once Weekly 5 mg and/or Maximum Tolerated Dose Versus Placebo for Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (SURMOUNT-MAINTAIN)Status: Active (not recruiting), Estimated PCD: 2026-05-22
Clinical trial
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study of Once-Weekly Tirzepatide Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With ObesityStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled TrialStatus: Completed, Estimated PCD: 2024-03-12
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or BothStatus: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 DiabetesStatus: Active (not recruiting), Estimated PCD: 2025-10-30
Clinical trial
Tirzepatide Study of Renal Function in People With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease Using Multiparametric Magnetic Resonance ImagingStatus: Recruiting, Estimated PCD: 2026-01-29
Clinical trial
A Randomized, Placebo-Controlled, Parallel-Arm Study to Investigate the Effect of Once-Weekly Tirzepatide on Energy Expenditure and Food Intake in Obese SubjectsStatus: Completed, Estimated PCD: 2022-05-26
Clinical trial
Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Overweight or Obesity - a Dose Finding StudyStatus: Recruiting, Estimated PCD: 2024-11-25
Clinical trial
A Randomized, Phase 3, Double Blind Trial Comparing the Effect of the Addition of Tirzepatide Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Participants With Type 2 DiabetesStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)Status: Completed, Estimated PCD: 2023-12-11
Clinical trial
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 InhibitorStatus: Recruiting, Estimated PCD: 2025-11-11
Clinical trial
A Dose-Escalation Treatment, Phase 1, Investigator- and Participant-Blind, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3457263 in Combination With Tirzepatide in Overweight or Obese ParticipantsStatus: Completed, Estimated PCD: 2023-06-08
Clinical trial
Effect of Tirzepatide on Oral Contraceptive Pharmacokinetics in Healthy Female SubjectsStatus: Completed, Estimated PCD: 2021-02-09
Clinical trial
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-4)Status: Completed, Estimated PCD: 2023-04-25
Clinical trial
A Multiple-Ascending Dose Study in Japanese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176Status: Completed, Estimated PCD: 2018-05-29
Clinical trial
A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a SulfonylureaStatus: Completed, Estimated PCD: 2021-11-01
Clinical trial
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)Status: Completed, Estimated PCD: 2023-04-20
Clinical trial
Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal FunctionStatus: Completed, Estimated PCD: 2019-08-19
Clinical trial
A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic ImpairmentStatus: Completed, Estimated PCD: 2020-09-22
Clinical trial
Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)Status: Completed, Estimated PCD: 2023-06-24
Clinical trial
Effect of Tirzepatide on Energy Intake and Appetite-and Reward-Related Brain Areas in Overweight/Obese Subjects: A Placebo-Controlled 6-Week Study With Functional MRIStatus: Completed, Estimated PCD: 2022-12-16
Clinical trial
A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 Years to 11 Years) With ObesityStatus: Recruiting, Estimated PCD: 2024-11-13
Clinical trial
A Bioequivalence Study to Compare the Pharmacokinetics of Tirzepatide Administered Subcutaneously by a Test Device (Test Formulation) Versus Reference Device (Reference Formulation) in Healthy ParticipantsStatus: Completed, Estimated PCD: 2023-07-17
Clinical trial
A Multiple Dose Titration Study in Chinese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TirzepatideStatus: Completed, Estimated PCD: 2021-08-17
Clinical trial
The Effect of Tirzepatide on α and β Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes MellitusStatus: Completed, Estimated PCD: 2021-04-08
Clinical trial
A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)Status: Completed, Estimated PCD: 2022-10-11
Clinical trial
Effect of Injection Site on the Relative Bioavailability of a Single Dose of Tirzepatide in Subjects With Low and High Body Mass IndicesStatus: Completed, Estimated PCD: 2020-04-03
Clinical trial
A Study to Compare the Pharmacokinetics of Tirzepatide Administered Subcutaneously by an Autoinjector Versus Prefilled Syringe in Healthy SubjectsStatus: Completed, Estimated PCD: 2019-12-16
Clinical trial
Effect of Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA): A Randomized, Double-Blind, Placebo-Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCTStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Towards a Personalized Precision Medicine in Rare Disease: Tirzepatide (a Dual Glucose-dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 Receptor Agonist) Monotherapy in Patients With Wolfram Syndrome Type 1Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
Role Of Metabolic Adaptation In Weight Regain: Expend Follow-UpStatus: Completed, Estimated PCD: 2024-05-24
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apitegromab in Overweight and Obese Adult SubjectsStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity: A Placebo-Matched Randomised Controlled TrialStatus: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/ObesityStatus: Not yet recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Investigational Tirzepatide Doses in Participants With Type 2 Diabetes and ObesityStatus: Recruiting, Estimated PCD: 2024-12-24
Clinical trial
Effect of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With ObesityStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for the Treatment of Obesity and Weight-Related Comorbidities in Adolescents: A Randomized, Double-Blind, Placebo- Controlled Trial (SURMOUNT-ADOLESCENTS-2)Status: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Feasibility TrialStatus: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
Comparative Effectiveness of Two Initial Combination Therapies in Patients With New Onset DiabetesStatus: Not yet recruiting, Estimated PCD: 2029-04-01
Clinical trial
Pilot Study of the Effect of Weight Loss by Pharmacotherapy on Chronic Pro-tumor Inflammatory CellsStatus: Recruiting, Estimated PCD: 2024-12-01
Document
DailyMed Label: MOUNJAROOrganization
Eli Lilly and Company
Document
DailyMed Label: ZEPBOUND